Stemline Therapeutics Inc (NASDAQ:STML) insider David Gionco sold 4,250 shares of the stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total value of $57,077.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Stemline Therapeutics Inc (STML) traded up $0.15 during trading hours on Friday, hitting $13.55. The company had a trading volume of 110,081 shares, compared to its average volume of 180,192. Stemline Therapeutics Inc has a twelve month low of $5.50 and a twelve month high of $16.20. The stock has a market capitalization of $340.11, a price-to-earnings ratio of -5.27 and a beta of -0.02.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. equities analysts anticipate that Stemline Therapeutics Inc will post -2.71 EPS for the current year.

Large investors have recently made changes to their positions in the stock. Voya Investment Management LLC purchased a new stake in shares of Stemline Therapeutics during the second quarter worth $102,000. Nationwide Fund Advisors raised its holdings in shares of Stemline Therapeutics by 7.2% during the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 855 shares in the last quarter. Alliancebernstein L.P. purchased a new stake in shares of Stemline Therapeutics during the second quarter worth $178,000. The Manufacturers Life Insurance Company raised its holdings in shares of Stemline Therapeutics by 40.1% during the second quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 5,522 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Stemline Therapeutics by 18.5% during the second quarter. Rhumbline Advisers now owns 27,358 shares of the biopharmaceutical company’s stock worth $252,000 after acquiring an additional 4,280 shares in the last quarter. Institutional investors and hedge funds own 50.24% of the company’s stock.

A number of analysts have recently issued reports on the company. BidaskClub upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the company a “buy” rating in a report on Thursday, December 14th. ValuEngine upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Finally, Cowen restated a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $33.75.

ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/19/david-gionco-sells-4250-shares-of-stemline-therapeutics-inc-stml-stock.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.